Trials / Completed
CompletedNCT00962741
Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis
A 2-Part Open-Label Study to Assess the Clinical Benefit and Long-Term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, or Psoriatic Arthritis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 127 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 2 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the effect of etanercept on the clinical benefit, safety, and physical functioning (ability to function in daily life) in children and adolescent subjects with 3 subtypes of childhood arthritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Etanercept | Etanercept 0.8 mg/kg QW up to a maximum dose of 50 mg |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2011-06-01
- Completion
- 2013-01-01
- First posted
- 2009-08-20
- Last updated
- 2014-06-10
- Results posted
- 2012-07-19
Locations
42 sites across 19 countries: Australia, Belgium, Colombia, Czechia, France, Germany, Hungary, Italy, Latvia, Lithuania, Mexico, Netherlands, Norway, Poland, Russia, Serbia, Slovakia, Slovenia, Spain
Source: ClinicalTrials.gov record NCT00962741. Inclusion in this directory is not an endorsement.